SerpinB3, a biomarker of taxane benefit in breast cancer

Elaina Susan Renata Collie-Duguid; Kathleen  Sweeney; Keith Nicol Stewart; Iain D Miller; Steven Darryll Heys

doi:10.1016/j.ejcsup.2010.06.036

SerpinB3, a biomarker of taxane benefit in breast cancer

Elaina Susan Renata Collie-Duguid, Kathleen Sweeney, Keith Nicol Stewart, Iain D Miller, Steven Darryll Heys

Applied Medicine

University of Aberdeen

Research output: Contribution to journal › Abstract

Abstract

Background: Lysosomal cathepsin proteases function in a programmed cell death (LPCD) pathway. Although there is evidence for the importance of this pathway in cancer cell survival, it has not been exploited in anti-cancer therapeutics. Hsp70 and serpinB3 can block this pathway and promote cell survival. Further-
more, serpinB3 is associated with lack of response to chemotherapy. Cathepsin mediated cell death is observed in response to anthracyclines or taxanes, which are widely utilised in breast cancer treatment.

Original language	English
Article number	O-35
Pages (from-to)	13
Number of pages	1
Journal	European Journal of Cancer. Supplement
Volume	8
Issue number	6
DOIs	https://doi.org/10.1016/j.ejcsup.2010.06.036
Publication status	Published - Sept 2010
Event	1st British Breast Cancer Research Conference - Nottingham, United Kingdom Duration: 15 Sept 2010 → 17 Sept 2010

Keywords

Breast cancer
treatment
biomarkers
serpinB3

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejcsup.2010.06.036Licence: Unspecified

Cite this

@article{15057eb5d3cd4d1abded941c83e246a4,

title = "SerpinB3, a biomarker of taxane benefit in breast cancer",

abstract = "Background: Lysosomal cathepsin proteases function in a programmed cell death (LPCD) pathway. Although there is evidence for the importance of this pathway in cancer cell survival, it has not been exploited in anti-cancer therapeutics. Hsp70 and serpinB3 can block this pathway and promote cell survival. Further-more, serpinB3 is associated with lack of response to chemotherapy. Cathepsin mediated cell death is observed in response to anthracyclines or taxanes, which are widely utilised in breast cancer treatment.",

keywords = "Breast cancer, treatment , biomarkers, serpinB3",

author = "Collie-Duguid, {Elaina Susan Renata} and Kathleen Sweeney and Stewart, {Keith Nicol} and Miller, {Iain D} and Heys, {Steven Darryll}",

year = "2010",

month = sep,

doi = "10.1016/j.ejcsup.2010.06.036",

language = "English",

volume = "8",

pages = "13",

journal = "European Journal of Cancer. Supplement",

issn = "1359-6349",

publisher = "Elsevier Limited",

number = "6",

note = "1st British Breast Cancer Research Conference ; Conference date: 15-09-2010 Through 17-09-2010",

}

TY - JOUR

T1 - SerpinB3, a biomarker of taxane benefit in breast cancer

AU - Collie-Duguid, Elaina Susan Renata

AU - Sweeney, Kathleen

AU - Stewart, Keith Nicol

AU - Miller, Iain D

AU - Heys, Steven Darryll

PY - 2010/9

Y1 - 2010/9

N2 - Background: Lysosomal cathepsin proteases function in a programmed cell death (LPCD) pathway. Although there is evidence for the importance of this pathway in cancer cell survival, it has not been exploited in anti-cancer therapeutics. Hsp70 and serpinB3 can block this pathway and promote cell survival. Further-more, serpinB3 is associated with lack of response to chemotherapy. Cathepsin mediated cell death is observed in response to anthracyclines or taxanes, which are widely utilised in breast cancer treatment.

AB - Background: Lysosomal cathepsin proteases function in a programmed cell death (LPCD) pathway. Although there is evidence for the importance of this pathway in cancer cell survival, it has not been exploited in anti-cancer therapeutics. Hsp70 and serpinB3 can block this pathway and promote cell survival. Further-more, serpinB3 is associated with lack of response to chemotherapy. Cathepsin mediated cell death is observed in response to anthracyclines or taxanes, which are widely utilised in breast cancer treatment.

KW - Breast cancer

KW - treatment

KW - biomarkers

KW - serpinB3

UR - https://www.researchgate.net/publication/251668268_O-35_serpinB3_a_biomarker_of_taxane_benefit_in_breast_cancer

U2 - 10.1016/j.ejcsup.2010.06.036

DO - 10.1016/j.ejcsup.2010.06.036

M3 - Abstract

SN - 1359-6349

VL - 8

SP - 13

JO - European Journal of Cancer. Supplement

JF - European Journal of Cancer. Supplement

IS - 6

M1 - O-35

T2 - 1st British Breast Cancer Research Conference

Y2 - 15 September 2010 through 17 September 2010

ER -

SerpinB3, a biomarker of taxane benefit in breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this